Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal

NCT04764656 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04764656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04764656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for Neovascular Age-related Macular Degeneration (nAMD) in Portugal
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Terminated
Start date
May 10, 2021
Completion date
February 16, 2024
Enrollment
81 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)